G6PD Deficiency Risk Factors References Glucose-6-phosphatase dehydrogenase (G6PD) deficiency is the most common enzyme deficiency in humans, affecting 400 million people worldwide. DRUGS TO AVOID IN G6PD DEFICIENCY DEFINITE RISK OF HAEMOLYSIS POSSIBLE RISK OF HAEMOLYSIS Pharmacological Class Drugs* Pharmacological Class Drugs* • ß-Naphthol drugs to avoid in G6PD deficiency FREE subscriptions for doctors and students. click here You have 3 open access pages. The following drugs should be avoided by patients with G6PD deficiency: Patients with G6PD deficiency are at risk for haemolytic crisis due to exposure to oxidative stressors like certain drugs, the surgical intervention per se, metabolic conditions (metabolic acidosis, ketoacidosis), and infections [5,17,18,28,44]. G6PD DEFICIENCY 361 5 dine compounds that are converted by @glucosidases to their aglycones, vicine and isouramil, respectively. These Drugs and Chemicals to be Avoided in G6PD Deficiency Drugs to be Avoided in G6PD Deficiency. There are different types of G6PD deficiency, an individual need to know the type of G6PD that they have inherited because each types of G6PD deficiency react to drugs differently and some may not react to some of the drugs and chemicals. [My hematologist] then admitted he didn’t know much about g6pd def. and if we had questions we should go to Dale. My specialized dr. Acknowledged dale to be the authority on g6pd def. G6PD Deficiency / Safe & Unsafe / Search All Drugs; Search All Drugs Search our database for drug names and trade names in all countries. Enter a drug name or trade name to view risk level. Not finding any results does not necessarily mean the drug is safe to take. Our database includes the most commonly used drugs that might pose a risk to G6PD deficient subjects. Please consult your. Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is an inherited, X Chromosome-linked, metabolic disorder. G6PD deficiency is known to be the most common enzyme disorder in humans. Its frequency has been reported in a wide range. Low-risk drugs which can probably be given in NORMAL THERAPEUTIC DOSES to G-6-PD-deficient subjects without nonspherocytic hemolytic anemia By Ernest Beutler, M.D. (see complete article here).